Diagnosis and management of follicular lymphoma: A comprehensive review

Dada, Reyad

doi:10.1111/ejh.13271

Cited by 38 publications

(33 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no standard therapy and the relapsing nature further necessitates serial treatment 33,34) . Novel approaches for relapsed or refractory FL have been studied such as: rituximab plus lenalidomide (ORR 64%, CR 20%); bruton tyrosine kinase (BTK) inhibitor ibrutinib (ORR 38%, CR 13%); bendamustine (ORR 63%, CR 12%); and obinutuzumab plus bendamustine followed by obinutuzumab maintenance (ORR 69%, CR 11%), whether as a single-agent or in combination 33) . Our study showed an ORR of 56.9% (CR rate of 15.8%) with copanlisib monotherapy in the indolent NHL cohort, which consisted mostly of FL (70%).…”

Section: Discussionmentioning

confidence: 99%

Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis

Subedi

Joshi

Gyawali

et al. 2021

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

Introduction:Copanlisib is an intravenous pan-class I PI3K inhibitor with predominant activity against the α and δ isoforms. We conducted this review to assess the efficacy and safety of copanlisib in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and other solid tumors. Methods: A systematic search of the electronic database (PubMed, Cochrane, Clinicaltrials.gov, Google scholar, and China National Knowledge Infrastructure) was conducted for relevant studies. Any clinical trial with clear outcome measures on the efficacy or safety of copanlisib in NHL or other solid tumors were eligible for inclusion. The objective response rate (ORR) and the complete response (CR) rate were used to assess the efficacy. Incidence of all grade and grade 3-4 treatmentemergent adverse events (TEAE) were calculated to evaluate the safety profile. Results: We analyzed seven single-arm prospective clinical trials. The pooled ORR was 39.1% (95% CI: 21.0-60.7%) for NHL cohort. The pooled CR rate for NHL was 10.9% (95% CI: 6.9-16.8%). Indolent NHL had a higher rate of response than aggressive NHL (ORR 56.9% vs. 22.8%; CR rate 15.8% vs. 7.6%). The pooled incidence rate of grade 3-4 TEAE was 73.9% (95% CI: 66.4-80.3%). Most common grade 3-4 TEAE were: hyperglycemia (31.4%), hypertension (29.8%), neutropenia (18.3%), anemia (7.4%), and pneumonia (6.8%). Conclusions: Copanlisib is effective in the treatment of relapsed or refractory NHL, with a higher rate of response in indolent NHL than aggressive NHL. Hyperglycemia and hypertension were the most common adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis

Subedi

Joshi

Gyawali

et al. 2021

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

show abstract

“…We then determined whether the ULA-MALC model was adapted for a larger scale drug testing assay. Thus, we tested five different drugs known to directly target different pathways in FL [2,41] and determined their efficacy based on: i) their impact on morphology (area and roundness) measurable on entire ULA-MALC and ii) cell death induction quantified in a dissociated or whole 3D model. Each molecule was also tested in the presence of RTX or GA101 as used in the clinic [2,42].…”

Section: Drug Sensitivity Testingmentioning

confidence: 99%

“…FL usually has an indolent course and excellent overall survival. However, the disease remains incurable with conventional approaches and is characterized by repeated relapses [1,2]. Thus, FL research should focus on the development of new and more efficient molecules targeting key pathways leading to disease pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma

Gava

Faria

Gravelle

et al. 2021

Cancers

View full text Add to dashboard Cite

Follicular lymphoma (FL) is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, which accounts for 20–30 percent of all non-Hodgkin lymphoma (NHL) cases. Great advances have been made to identify the most relevant targets for precision therapy. However, no relevant models for in vitro studies have been developed or characterized in depth. To this purpose, we generated a 3D cell model from t(14;18)-positive B-NHL cell lines cultured in ultra-low attachment 96-well plates. Morphological features and cell growth behavior were evaluated by classical microscopy (2D imaging) and response to treatment with different drugs was evaluated by a high-content analysis system to determine the robustness of the model. We show that the ultra-low attachment (ULA) method allows the development of regular, spherical and viable ULA-multicellular aggregates of lymphoma cells (MALC). However, discrepancies in the results obtained after 2D imaging analyses on drug-treated ULA-MALC prompted us to develop 3D imaging and specific analyses. We show by using light sheet microscopy and specifically developed 3D imaging algorithms that 3D imaging and dedicated analyses are necessary to characterize morphological properties of 3D models and drug effects. This study proposes a new method, but also imaging tools and informatic solutions, developed for FL necessary for future preclinical studies.

show abstract

“…Adding rituximab or chemotherapy to radiation lacks an overall survival benefit, and thus it is not recommended. [ 59 ] In affected body regions with nonbulky disease where radiation is expected to cause significant morbidity (i.e., abdomen), observation is a reasonable option. Patients with bulky disease may be treated with chemotherapy regimens, as in advanced stages of disease.…”

Section: Indolent Lymphomamentioning

confidence: 99%

Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic

Alzahrani¹,

Al-Mansour²,

Apostolidis³

et al. 2020

Saudi J Med Med Sci

Self Cite

View full text Add to dashboard Cite

The Saudi Lymphoma Group had previously published recommendations on the management of the major subtypes of lymphoma. However, the effect the currently ongoing coronavirus disease 2019 (COVID-19) pandemic has on the management of patients with lymphoma has been paramount. Therefore, the Saudi Lymphoma Group has decided to provide clinical practice guidelines for the diagnosis, management and follow-up of patients with various types of lymphoma during the COVID-19 pandemic.

show abstract

Diagnosis and management of follicular lymphoma: A comprehensive review

Cited by 38 publications

References 79 publications

Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis

Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis

3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma

Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic

Contact Info

Product

Resources

About